PT1616011E - Polipeptídeos quiméricos e a sua utilização - Google Patents
Polipeptídeos quiméricos e a sua utilização Download PDFInfo
- Publication number
- PT1616011E PT1616011E PT04727873T PT04727873T PT1616011E PT 1616011 E PT1616011 E PT 1616011E PT 04727873 T PT04727873 T PT 04727873T PT 04727873 T PT04727873 T PT 04727873T PT 1616011 E PT1616011 E PT 1616011E
- Authority
- PT
- Portugal
- Prior art keywords
- dna
- activity
- activities
- chimeric molecules
- region
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000000694 effects Effects 0.000 abstract 5
- 108020004414 DNA Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000002141 anti-parasite Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000003096 antiparasitic agent Substances 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000005782 double-strand break Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000000051 modifying effect Effects 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000022983 regulation of cell cycle Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000821A ITMI20030821A1 (it) | 2003-04-18 | 2003-04-18 | Polipeptidi chimerici e loro uso. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1616011E true PT1616011E (pt) | 2008-01-07 |
Family
ID=33187374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04727873T PT1616011E (pt) | 2003-04-18 | 2004-04-16 | Polipeptídeos quiméricos e a sua utilização |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20060292629A1 (enExample) |
| EP (1) | EP1616011B1 (enExample) |
| JP (2) | JP4794432B2 (enExample) |
| KR (2) | KR101360781B1 (enExample) |
| CN (1) | CN100584950C (enExample) |
| AT (1) | ATE374826T1 (enExample) |
| AU (1) | AU2004230254B2 (enExample) |
| CA (1) | CA2522525A1 (enExample) |
| CY (1) | CY1107115T1 (enExample) |
| DE (1) | DE602004009301T2 (enExample) |
| DK (1) | DK1616011T3 (enExample) |
| ES (1) | ES2293247T3 (enExample) |
| IT (1) | ITMI20030821A1 (enExample) |
| PL (1) | PL1616011T3 (enExample) |
| PT (1) | PT1616011E (enExample) |
| WO (1) | WO2004092194A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20030821A1 (it) * | 2003-04-18 | 2004-10-19 | Internat Ct For Genetic En Gineering And | Polipeptidi chimerici e loro uso. |
| NL1027479C2 (nl) * | 2004-10-21 | 2006-05-01 | Synvolux Ip B V | Bescherming van biologisch actieve moleculen met behulp van amphifielen. |
| ES2341796T3 (es) * | 2005-02-18 | 2010-06-28 | Astrazeneca Ab | Metodo para determinar la capacidad de respuesta a los inhibidores de chk1. |
| GB0609119D0 (en) * | 2006-05-09 | 2006-06-21 | Univ Birmingham | Histones |
| US8552168B2 (en) * | 2007-05-11 | 2013-10-08 | The Regents Of The University Of California | Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them |
| AU2015216822A1 (en) | 2014-02-17 | 2016-09-01 | Centre Leon Berard | Predictive method of characterizing the radiosensitivity and tissular reaction of a patient to therapeutic ionizing radiation |
| CN104193826B (zh) * | 2014-09-17 | 2018-02-23 | 山东大学齐鲁医院 | 一种融合多肽及其在制备抗肿瘤药物中的应用 |
| CA3019629A1 (en) * | 2016-04-12 | 2017-10-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency |
| JP6925003B2 (ja) * | 2016-05-10 | 2021-08-25 | 公立大学法人横浜市立大学 | 非相同末端連結欠損細胞及びその利用 |
| MX2018014366A (es) * | 2016-05-27 | 2019-04-11 | Synthex Inc | Interfaces de proteina. |
| KR20190020727A (ko) * | 2016-06-09 | 2019-03-04 | 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 | 변형된 당단백질 b를 갖는 헤르페스 바이러스 |
| EP3638317A4 (en) | 2017-06-15 | 2021-03-17 | The Regents of The University of California | TARGETED NONVIRAL DNA INSERTIONS |
| KR102770787B1 (ko) | 2017-10-27 | 2025-02-19 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
| WO2019104244A1 (en) | 2017-11-22 | 2019-05-31 | Synthex, Inc. | Peptides for inhibiting rad51 |
| PE20241173A1 (es) | 2021-10-14 | 2024-05-28 | Arsenal Biosciences Inc | Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica |
| CA3238209A1 (en) | 2021-12-16 | 2023-06-22 | Christian Kuhne | Cell penetrating polypeptides (cpps) and their use in human therapy |
| CN116023512A (zh) * | 2023-02-16 | 2023-04-28 | 浙江大学 | 一条靶向dna损伤修复蛋白的多肽及其用途 |
| EP4480497A1 (en) | 2023-06-21 | 2024-12-25 | RDP Pharma AG | Bio-conjugates for oncology |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747641A (en) * | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
| EP1147209A2 (en) * | 1999-02-03 | 2001-10-24 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| JP2002539839A (ja) * | 1999-03-31 | 2002-11-26 | インヴィトロゲン・コーポレーション | 転位ポリペプチドによる機能性タンパク質配列の送達 |
| WO2001074905A1 (en) * | 2000-04-03 | 2001-10-11 | Antisoma Research Limited | Compounds for targeting |
| GB0112818D0 (en) * | 2001-05-25 | 2001-07-18 | Lorantis Ltd | Conjugate |
| EP1342781A1 (en) * | 2002-03-09 | 2003-09-10 | ARTEMIS Pharmaceuticals GmbH | Recombinase fusion protein with enhanced cellular uptake |
| US9447434B2 (en) * | 2002-09-05 | 2016-09-20 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| ITMI20030821A1 (it) * | 2003-04-18 | 2004-10-19 | Internat Ct For Genetic En Gineering And | Polipeptidi chimerici e loro uso. |
-
2003
- 2003-04-18 IT IT000821A patent/ITMI20030821A1/it unknown
-
2004
- 2004-04-16 CN CN200480009095A patent/CN100584950C/zh not_active Expired - Fee Related
- 2004-04-16 PL PL04727873T patent/PL1616011T3/pl unknown
- 2004-04-16 PT PT04727873T patent/PT1616011E/pt unknown
- 2004-04-16 JP JP2006505169A patent/JP4794432B2/ja not_active Expired - Fee Related
- 2004-04-16 KR KR1020057019839A patent/KR101360781B1/ko not_active Expired - Fee Related
- 2004-04-16 CA CA002522525A patent/CA2522525A1/en not_active Abandoned
- 2004-04-16 KR KR1020117013324A patent/KR101247704B1/ko not_active Expired - Fee Related
- 2004-04-16 EP EP04727873A patent/EP1616011B1/en not_active Expired - Lifetime
- 2004-04-16 DK DK04727873T patent/DK1616011T3/da active
- 2004-04-16 DE DE602004009301T patent/DE602004009301T2/de not_active Expired - Lifetime
- 2004-04-16 AU AU2004230254A patent/AU2004230254B2/en not_active Ceased
- 2004-04-16 US US10/546,661 patent/US20060292629A1/en not_active Abandoned
- 2004-04-16 WO PCT/EP2004/004062 patent/WO2004092194A2/en not_active Ceased
- 2004-04-16 AT AT04727873T patent/ATE374826T1/de active
- 2004-04-16 ES ES04727873T patent/ES2293247T3/es not_active Expired - Lifetime
-
2007
- 2007-12-28 CY CY20071101640T patent/CY1107115T1/el unknown
-
2009
- 2009-11-12 US US12/616,859 patent/US20110033384A1/en not_active Abandoned
-
2011
- 2011-03-09 JP JP2011051784A patent/JP2011182792A/ja active Pending
-
2014
- 2014-09-05 US US14/479,045 patent/US20150018409A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN100584950C (zh) | 2010-01-27 |
| KR20110074948A (ko) | 2011-07-04 |
| KR101247704B1 (ko) | 2013-03-26 |
| WO2004092194A3 (en) | 2005-03-17 |
| KR20060003029A (ko) | 2006-01-09 |
| CN1768142A (zh) | 2006-05-03 |
| US20110033384A1 (en) | 2011-02-10 |
| CY1107115T1 (el) | 2012-01-25 |
| JP4794432B2 (ja) | 2011-10-19 |
| JP2006523448A (ja) | 2006-10-19 |
| CA2522525A1 (en) | 2004-10-28 |
| EP1616011B1 (en) | 2007-10-03 |
| DE602004009301T2 (de) | 2008-07-17 |
| WO2004092194A2 (en) | 2004-10-28 |
| AU2004230254B2 (en) | 2008-10-02 |
| JP2011182792A (ja) | 2011-09-22 |
| PL1616011T3 (pl) | 2008-05-30 |
| US20060292629A1 (en) | 2006-12-28 |
| ES2293247T3 (es) | 2008-03-16 |
| ITMI20030821A1 (it) | 2004-10-19 |
| DK1616011T3 (da) | 2008-02-04 |
| DE602004009301D1 (de) | 2007-11-15 |
| US20150018409A1 (en) | 2015-01-15 |
| KR101360781B1 (ko) | 2014-04-24 |
| AU2004230254A1 (en) | 2004-10-28 |
| ATE374826T1 (de) | 2007-10-15 |
| EP1616011A2 (en) | 2006-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1616011T3 (pl) | Chimeryczne polipeptydy i ich zastosowanie | |
| Dunnill | Triplet Nucleotide–Amino-acid Pairing; a Stereo-chemical Basis for the Division between Protein and Non-protein Amino-acids | |
| Yamanaka et al. | A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system | |
| EP2540309A3 (en) | Tissue protective peptides and uses thereof | |
| CA2345903A1 (en) | Molecular pathogenicide mediated plant disease resistance | |
| WO2006024547A3 (en) | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use | |
| ATE380828T1 (de) | Modifizierte peptide als therapeutische mittel | |
| EP3196213A3 (en) | Antibodies directed to her-3 and uses thereof | |
| WO2003076592A3 (en) | Novel method for delivery and intracellular synthesis of sirna molecules | |
| WO2006128668A3 (en) | Coagulation factor x polypeptides with modified activation properties | |
| WO2001027158A3 (en) | Olfactory receptor sequences | |
| WO2002000721A3 (en) | Cytokine receptor zcytor17 | |
| WO2009001260A3 (en) | Cosmetic use of apolipoprotein d type proteins | |
| WO2006029078A3 (en) | Targeting transducible molecules to specific cell types | |
| Okuma et al. | A Macrocyclic Peptide Library with a Structurally Constrained Cyclopropane‐containing Building Block Leads to Thiol‐independent Inhibitors of Phosphoglycerate Mutase | |
| PL2255834T3 (pl) | Projektowanie rusztowania z zastosowaniem czynników zasiedlania | |
| WO2002044409A3 (en) | Substrate linked directed evolution (slide) | |
| WO2007060213A3 (en) | Erythropoietin polypeptides and uses thereof | |
| WO2007013358A3 (en) | Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent | |
| ES2274771T3 (es) | Catalizador clorado y fluorado que comprende un metal del grupo viii y un metal adicional y su uso en la hidrogenacion de composiciones aromaticas. | |
| WO2001085912A3 (en) | Presenilin enhancers | |
| WO2005079490A3 (en) | Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides | |
| WO2001094952A3 (en) | Methods and compositions for modulating oxidized ldl transport | |
| WO2003087332A3 (en) | Novel polynucleotides encoding the human citron kinase polypeptide, bmsnkc 0020/0021 | |
| WO2005062788A3 (en) | Prostate specific proteins expressed in cancer and methods of use thereof |